

Index

A

ABCD, 314
absorption, 5
 elderly, 349
 liver disease affecting, 338
 long-acting insulin, factors affecting, 195–196
 renal impairment affecting, 335
 short-acting insulin
 factors affecting, 180
 improving, 180–190
acarbose, 229–238, 317, 336, 340
ACCORD, 295, 342–343, 345
ACCORDION, 343–344
ACE, 233, 236–237, 237
ACT NOW (Actos Now), 251, 252
acute coronary syndromes, 143–145, 345–346
ADA, *see* American Diabetes Association
adherence issues, 329–330
adolescents/young people, 184, 225–226, 318
ADOPT, 37, 53–54, 241–242, 244, 248
ADVANCE and ADVANCE-ON, 55, 59–60, 63–64, 342–344, 345
adverse effects, *see* safety
agonists, 3, 4
 dual and triple, 274–293, 291
 partial, 4
AiDAPT, 227
albiglutide, 136, 139, 140, 144, 149
aleglitazar, 253
alogliptin, 70, 72–73, 76–77, 80, 82, 83, 85–86, 90, 334, 336, 338
alpha glucosidase inhibitors, 229–238
ambulatory glucose monitoring, 221
American College of Clinical Endocrinologists, 305–306
American College of Endocrinology, 305–306
American Diabetes Association (ADA)
 European Association for the Study of Diabetes and (ADA/EASD) consensus, 91–92, 217, 226, 254, 294, 302–305, 305, 306–307, 310–311, 319
 on insulin pumps, 226
 pregnancy and, 312–313
 Standards of Medical Care in Diabetes (2022), 297
AMP-activated protein kinase (AMPK), 34
AMPLITUDE-0, 144, 150–151, 151

amputation, 104–105
amylin, 258, 271
anagliptin, 74
antagonist, 3
antiobesity drugs, 257, 265–270, 271
antiplatelet therapy, 345
Association of British Clinical Diabetologists (ABCD), 314
AWARD-1 and -6, 138

B

bamadutide, 286
basal bolus insulin, 140–141, 180, 187, 191, 210, 217, 309, 314, 318, 333
basal insulin Fc, 210
basal insulin peglispro, 205
beef (bovine) insulin, 165, 166, 169
Beer's criteria, 327–328
BEGIN series, 201
beta cells, 51, 52, 61, 131, 162, 261, 275, 276
biguanides, 306
 history, 31
 see also metformin
bile acid sequestrants, 260–262
biliary excretion, 339
bioavailability and renal impairment, 335
biosimilar drugs
 generic drugs vs., 17
 insulins, 16–18, 186, 205
biphasic insulin, 168, 202
bladder cancer, 245
blood flow, hepatic, altered, 339
blood pressure, 345
 management, 325, 329, 345
 SGLT2 inhibitors and, 103
 see also hypertension
bone fractures, 105, 244–245, 247, 248, 249
bovine (beef) insulin, 165, 166, 169
breastfeeding, 348
BRIGHT, 205
bromocriptine, 257, 258, 262–264, 271
buccal insulin delivery, 192
bupropion/naltrexone, 257, 268–269

C

C-cell carcinomas, 142
CamAPS, 224

- canagliflozin, 95, 96, 98–99, 102, 104–105, 106, 108, 111–112, 118, 122, 134, 334, 336, 338, 347
- cancer (malignancy)
- bladder, 245
 - insulin analogues and, 209
 - pancreatic, 80–81, 143, 146, 147, 149
 - thyroid, 9, 142–143, 149, 150, 151
- CANOE, 43, 44, 251–252
- CANVAS, 98, 104, 105, 106, 107, 108, 109, 111, 112, 114, 118
- carbohydrate and insulin, 164, 165, 171
- cardiovascular disease, prescribing, 340–347
- cardiovascular safety (incl. outcome trials/CVOT), 12–14, 300, 342–343, 344–345
- alpha glucosidase inhibitors, 235–237
 - bromocriptine, 263–264
 - colesevelam, 262
 - DPP-4 inhibitors, 82–89
 - glitazones, 13, 242, 243–244, 245–250
 - GLP-1 receptor agonists, 124, 137, 141, 143–152, 156
 - GLP-1/GIP receptor dual agonists, 280
 - guidelines and, 298, 300, 301, 303, 304, 305, 307, 318
 - metformin, 38–42
 - naltrexone/bupropion, 268–269
 - nateglinide, 62
 - phentermine/topiramate, 270
 - rosiglitazone, 13, 243–244
 - SGLT2 inhibitors, 105–110, 115
 - sulfonylureas, 56–58
 - tirzepatide, 280, 282
 - see also* heart failure
- CARMELINA, 83, 85, 88, 89, 90, 91
- CAROLINA, 56, 60, 63–64, 65, 83, 85, 88
- children, 348–349
- and adolescents/young people, 184, 225–226, 318
- Child–Pugh score, 337
- chimeric peptides, 277
- chloroquine, 267
- cholelithiasis, 143
- Clarke score, 332
- clearance, 6
- in renal impairment, 335
 - see also* elimination; excretion
- clinical pharmacology, *see* pharmacology
- clinical trials (basics), 8, 11–12
- clinician factors in therapeutic inertia, 324–326
- closed-loop insulin systems, 223, 225
- hybrid, 224–225
- co-agonists, 277
- colesevelam, 257, 257–258, 260–262, 271
- colestimide, 261
- colestyramine, 260, 262
- comparison, indirect, 25–26
- compliance (adherence) issues, 329–330
- CONCEPTT, 223, 226
- CONCLUDE, 204–205
- consensus reports, 295
- ADA/EASD, 91–92, 217, 226, 254, 294, 302–305, 305, 306–307, 307, 310–311, 319
- continuous glucose monitoring (CGM), 214, 217, 218–225, 226–227
- flash, 219, 220–221, 351
- COR-Diabetes, 268
- coronary artery disease, 340–345
- acute coronary syndromes, 143–145, 345–346
 - SPREAD-DIMCAD, 40, 41–42
 - see also* acute coronary syndrome
- cost–utility analysis, 21, 22
- cotadutide, 216, 274, 285–286
- COVID-19, 122–123, 318
- CREDENCE, 105, 111–112, 114
- CVD-REAL series, 109, 110, 115
- Cycloset safety trial, 263–264
- ## D
- DAFNE, 210, 217, 227, 350
- DAPA-HF, 116, 117, 118–119, 347
- dapagliflozin, 14, 25, 95, 96, 97–98, 100, 101, 102, 103, 106, 108, 111, 112–113, 116, 117, 119–121, 123–124, 125, 334, 336, 347
- DARE-19, 123–124
- Dawn phenomenon, 172, 173
- DCCT, 173–174, 175, 176, 222, 297
- DECLARE-TIMI 58, 98, 104, 106, 107, 108, 112, 114
- DELIVER, 116, 117
- developing (under-resourced) countries, 291, 311, 316–318
- development (drug), 2, 7–12
- future developments, 26–27
 - insulin, 14–18
- DEVOTE, 202, 204
- diabetes
- antiobesity drugs in, 268, 270, 271
 - coronary artery disease and, 340–345
 - drug guidelines, 294–321
 - gestational, 35, 44, 311, 312, 313, 347, 351

heart failure and, 346–347
 ketoacidosis (DKA), 103–104, 120,
 122–123, 125
 kidney disease, *see* kidney disease
 liver disease and, 337–339
 structured education in management, 177,
 191, 210, 217, 308
see also type 1 diabetes; type 2 diabetes
 DIAMOND, 112, 223
 diet
 acarbose and, 232
 cardiovascular risk in type 2 diabetes, 341
 see also food intake
 DIGAMI and DIGAMI-2, 346
 dipeptidyl peptidase-4 (DPP-4)
 inhibitors (gliptins), 3, 5, 67–94, 139, 299, 301,
 306, 315, 317, 334, 336, 340
 structure and function, 68
 discovery (drug), 3
 insulin, 165
 distribution, 5–6
 elderly, 349
 volume of, in liver disease, 339
 DIY Closed Loop, 225
 dopamine receptor agonist, 262, 263
 dose–response relationships, 4–5
 DPP (Diabetes Prevention Programme),
 42–44, 251
 DPP-4, *see* dipeptidyl peptidase-4
 DREAM, 243, 251, 252
 dual agonists, 275–287, 291
 DUAL VII, 140
 dulaglutide, 135, 138, 139, 144, 148–149, 278–
 279, 334, 336, 338
 DURATION series, 101, 107, 137

E

EASD/ADA (EASD;
 American Diabetes Association/European
 Association for the Study of Diabetes) con-
 sensus, 91–92, 217, 226, 254, 294, 302–305,
 305, 306–307, 307, 310–311, 319
 EASE-2/EASE-3, 120, 121
 economics, *see* cost; pharmacoeconomics
 EDIC, 174, 176, 297
 EDITION, 203–204
 education (patient), 122, 326, 332–333
 structured, 177, 191, 210, 217, 308
 efficacy, 7–8
 glycaemic, *see* glycaemic efficacy
 efinopegdutide, 274, 287, 291
 efpeglenatide, 136, 144, 150–151

elderly, prescribing, 322, 327, 349–350
 ELEMENT series, 205
 elimination, 6–7
 see also clearance; excretion
 ELIXA, 134, 143–145, 151, 152
 EMA, *see* European Medicines Agency
 EMPA-KIDNEY, 111, 114
 EMPA-REG series, 95, 99, 104, 105–106, 109,
 113–114, 116
 empagliflozin, 96, 99, 102, 105–106, 111, 113–
 114, 116–118, 120, 121, 125, 139, 329, 334,
 336, 338, 347
 EMPEROR series, 116–117, 118, 347
 enzyme (action on), 4
 indication and inhibition, 7
 EQ-5D (EuroQoL Dimensions), 23
 ertugliflozin, 96, 99, 100, 106, 109, 114,
 118, 334, 338
 ESC (European Society of Cardiology), 305–307
 European Association for the Study of Diabetes/
 American Diabetes Association (ADA/
 EASD) consensus, 91–92, 217, 226,
 254, 294, 302–305, 305, 306–307, 307,
 310–311, 319
 European Medicines Agency (EMA), 10
 insulin and, 14
 European Society of Cardiology (ESC), 305–307
 EuroQoL Dimensions (EQ-5D), 23
 evidence-based guidelines, 295
 evogliptin, 74
 EXAMINE, 82, 83, 85–86, 90, 91
 excretion
 biliary, 339
 elderly, 349
 renal, 7
 see also clearance; elimination
 exenatide, 101, 102, 133–134, 137, 138, 140, 143,
 144, 147–148, 336, 338
 exendin, 132, 136, 150, 151–152
 EXSCEL, 144, 147–148, 148, 152

F

fasting hyperglycaemia, 172–173
 fatty acid residues addition to insulin, 196
 see also lipids
 fatty liver disease, non-alcoholic, 155, 287
 FDA (Food and Drug Administration), 10, 13, 14
 flash continuous glucose monitoring, 219,
 220–221, 351
 FLOW, 153
 Food and Drug Administration (FDA), 10, 13, 14
 food intake and insulin, 163–165

see also diet

4-T trial, 201

fractures, 105, 244–245, 247, 248, 249

Freestyle Libre, 220–221

G

gallstones, 143

gastrointestinal (intestinal/gut) side effects, 34,
150, 232, 258, 267, 269, 279, 285–286

gemigliptin, 74

genitourinary infections, 103

gestational diabetes, 35, 44, 311, 312,
313, 347, 351

GETGOAL-X, 137

GIP, *see* glucose-dependent insulinotropic
polypeptide

glibenclamide (glyburide), 36, 37, 52,
242, 313, 313

gliclazide, 52, 314–315, 334

glimepiride, 53, 54, 60, 63, 79, 88, 140, 334

glimins, 288

glipizide, 41–42, 53, 314–315

gliptins (DPP-4 inhibitors), 3, 5, 67–94, 139, 299,
301, 306, 315, 317

glitazars, 252–253

glitazones (thiazolidinediones), 60, 239–256,
306, 307, 315

prescribing, 244, 245, 250, 335, 339, 342, 346
type 2 diabetes, 253–254, 298, 301, 315
prevention, 251–252

GLP-, 1 *see* glucagon-like peptide-1

glucagon, 276, 277, 331

administration, 77, 330, 331

glucagon/GLP-1/GIP triagonist, 274, 287, 291
receptor, 276

glucagon-like peptide-1 (GLP-1), 5, 68,
275, 276, 277

glucagon-like peptide-1 (GLP-1)

receptor, 131, 276

agonists, 5, 101–102, 130–161, 271, 299, 301,
304, 306, 317, 352

dual GIP and, 278–285, 291

prescribing, 133–134, 134, 135, 136, 147,
152, 322, 335, 338, 340, 345, 346, 352

triple GIP and glucagon, 274, 287, 291

gluconeogenesis (hepatic), inhibition, 33–34
glucose-dependent insulinotropic polypeptide
(GIP), 68, 275, 276, 277

multiagonists for GLP-, 1 and glucagon and
see glucagon-like peptide-1 receptor

glucose monitoring and control (self),
218–225, 299

cardiovascular disease and, 342–344

case (in type 1 diabetes), 351

continuous, *see* continuous glucose
monitoring

see also hyperglycaemia; hypoglycaemia

glyburide (glibenclamide), 36, 37, 52, 242, 313

glycaemic control, *see* glucose monitoring
and control

glycaemic efficacy

alpha glucosidase inhibitors, 231–232

bromocriptine, 262, 263

colesevelam, 261–262

DPP-4 inhibitors, 75, 78

GLP-1 receptor agonists, 137–142

hydroxychloroquine, 265

imeglimin, 288–289

insulin analogues, 198, 200–201, 201–202,
203–205, 207–208

insulin pumps, 216–217

metformin, 36–37

orlistat, 266–267

pioglitazone, 241–242

pramlintide, 259–260

SGLT2 inhibitors, 100–105

sulfonylureas, 53

Gold score, 332

GRADE, 54, 79, 101, 140, 198

guidelines (antidiabetic drug), 294–321

gut (intestine/gastrointestinal tract), side effects,
34, 150, 232, 258, 267, 269, 279, 285–286

H

HARMONY, 140, 144, 149, 152

HbA1c

conversion charts, 357–358

targets (guidelines), 295–297, 298, 300, 310, 329

health economic modelling, 23–25

healthcare system and therapeutic

inertia, 324, 326

heart failure (HF), 307, 342, 346–347

diabetes and, 346–347

gliptins and, 346

glitazones (thiazolidinediones) and, 244, 246,
247, 248, 249, 307, 346

GLP-1 receptor agonists and, 152, 307, 346

metformin and, 35, 307

SGLT2 inhibitors and, 106, 107, 108, 110,
116–119, 124–125, 307, 346

hepatic..., *see* liver

HI-5 study, 346

history

biguanides, 31

dapagliflozin, 15

insulin, 165

insulin devices, 215, 215–216
 sulfonyleureas, 50
 HM12525A (efinopegdutide), 274, 287, 291
 HM15211 (LAPS Triple Agonist), 274, 287, 291
 HOME, 39–41
 human insulin, 169–170, 171, 172, 173,
 176–177, 182
 guidelines, 302, 311, 317–318
 isophane (NPH) insulin, 166, 167–168, 172,
 177, 184, 195, 197, 198, 200, 201, 206, 207,
 208, 210, 311, 312, 318
 hybrid closed loop insulin system, 224–225
 hybrid peptides, 277
 hydroxychloroquine, 257, 264–265, 271
 hyperglycaemia
 in diabetic kidney disease, management
 guidelines, 314–315
 morning/fasting, 172–173
 in renal impairment, 333–335
 in type 2 diabetes, management guide-
 lines, 295–296
 hypertension and diabetes, 341
 hypoglycaemia, 330–333
 acarbose, 232
 elderly, 350
 insulin, 15, 175, 271, 330–333
 human insulin, 170
 in intensified therapy, 175
 long-acting analogues, 200–201, 201–202,
 202–203, 203–205, 207, 208, 209
 nocturnal, 173, 198, 201, 207, 208, 209
 problematic, 330–333
 reporting in trials, 16
 short-acting analogues, 185, 188, 189
 sulfonyleureas, 55

I

ICGP (Irish College of General Practitioners),
 296, 298–299, 300–302
 IDF (International Diabetes Federation), 296,
 297, 298–299, 307–308, 311, 315–316, 318
 IDPP (Indian Diabetes Prevention Programme),
 44, 251–252
 imeglimin, 274, 288–290, 291
 incretins, 68, 80–81, 131, 275, 277, 291, 336
 Indian Diabetes Prevention Programme (IDPP),
 44, 251–252
 indirect comparison, 25–26
 infections, genitourinary, 103
 inhaled insulin, 190
 INSTRIDE, 205
 insulin, 14–18, 139–140, 140–141, 161–
 228, 308–311
 animal, 169, 170
 basal bolus, 140–141, 180, 187, 191, 210, 217,
 309, 314, 318, 333
 biosimilar, 16–18, 186, 205
 development and licensing, 14–18
 devices, 206, 214–229
 pens, 215
 pumps, 184, 215–218, 223–226
 gestational diabetes, 313
 GLP-1 agonists combined with, 140–141
 GLP-1 agonists compared with, 139–140
 guidelines, 302, 304, 311, 314, 317–318
 hepatic impairment and, 338–340
 human, *see* human insulin
 hypoglycaemia, *see* hypoglycaemia
 intensified therapy, 173–176, 190–191
 intermediate-acting, 171–172
 limitations of older insulins, 170–173
 long-acting, 171–172, 194–213
 mixed/premixed, 172, 181, 183, 184, 309, 317
 novel/alternative routes of delivery, 191–192
 physiology, 163–165
 prescribing, *see* prescribing
 production, 16, 165–170
 receptor, 162
 renal impairment/kidney disease
 and, 314, 337
 resistance, reduced, 34, 45, 240, 245, 249
 short/fast-acting, 171
 structure, 161–162
 sulfonyleureas and secretion of, 51
 type 1 diabetes, 176, 308–311
 type 2 diabetes, 177, 302, 304, 306
 insulin analogues, 179–213
 long-acting, 194–213, 317
 manufacture, 180–181
 short/fast/rapid-acting, 179–193, 302, 309,
 310, 311, 312, 317
 combined with long-acting, 206
 type 2 diabetes, 207–208, 302
 ultrafast-acting, 186–189
 insulin aspart, 181, 182, 183–184, 186, 206
 fast-acting, 181, 186–188
 ultrafast-acting, 181, 188–189
 insulin degludec, 197, 200, 201–203, 204,
 206, 207, 208
 liraglutide and, 135, 140–141, 201
 insulin detemir, 101, 187, 197, 199–201, 207, 208
 insulin glargine, 16, 54, 79, 101, 134, 141, 168,
 182, 188, 189, 196, 197, 197–199, 200, 201,
 202, 203–205, 206, 207, 208, 209, 309
 lixisenatide and, 134, 141
 type 1 diabetes, 308, 309, 311, 312

insulin glulisine, 181, 184–185
 insulin icodex, 196, 197, 210
 insulin isophane (NPH insulin), 166, 167–168, 172, 177, 184, 195, 197, 198, 200, 201, 206, 207, 208, 210, 311, 312, 318
 insulin lispro, 181, 182–183, 184, 186, 206
 pegylated (pegglispro), 205
 ultra-rapid, 181, 188–189
 insulin zinc suspension, 166–167
 inTandem1 series, 120, 121, 122
 interchangeability of biosimilars, 18
 intermittently scanned (flash) continuous glucose monitoring, 219, 220–221, 351
 IDCL, 225
 International Diabetes Federation (IDF), 296, 297, 298–299, 307–308, 311, 315–316, 318
 intestinal (gastrointestinal/gut) side effects, 34, 150, 232, 258, 267, 269, 279, 285–286
 IRIS, 246, 249
 Irish College of General Practitioners (ICGP), 296, 298–299, 300–302
 Irish Department of Health, 308
 islet amyloid polypeptide (amylin), 258, 271
 islet cells
 beta, 51, 52, 61, 131, 162, 261, 275, 276
 transplantation, 333
 isophane (NPH) insulin, 166, 167–168, 172, 177, 184, 195, 197, 198, 200, 201, 206, 207, 208, 210, 311, 312, 318

J

JNJ-64565111 (efinopegdutide), 274, 287, 291

K

KDIGO, 313
 ketoacidosis, diabetic (DKA), 103–104, 120, 122–123, 125
 kidney (renal...)
 excretion via, 7
 renal outcome
 DPP-4 inhibitors, 89–91
 GLP-1 receptor agonists, 152–153
 metformin, 42
 SGLT2 inhibitors, 110–115
 kidney disease (nephropathy and renal impairment), chronic/diabetic (CKD/DKD), 42, 70, 74, 89, 91, 100, 111, 112–113, 124–125, 152, 290, 313–315, 335, 336, 336
 guidelines, 303, 313–315
 prescribing, 35, 333–337

L

lactic acidosis, 31–32, 37–38, 335

LAPS Triple Agonist, 274, 287, 291
 LEAD-6, 137
 LEADER, 144, 145–146, 152
 LEAN, 155
 lente insulin, 166, 167, 196
 licensing, 12–14
 lifestyle and cardiovascular risk in type 2 diabetes, 341
 limb amputation, 104–105
 linagliptin, 56, 60, 70, 73, 76–77, 83, 87–88, 90–91, 334, 336, 338
 lipids
 cardiovascular risk and, 341, 345
 glitazones effects and, 242
 GLP-1 receptor agonist effects, 142
 insulin actions, 164, 165
 liraglutide, 9, 134–135, 137, 138, 144, 145–146, 153–155, 155, 285, 286, 287, 306, 335, 336, 338
 and insulin degludec, 135, 140–141, 201
 liver (hepatic...), 337–340
 alogliptin effects, 82
 inhibition of glucose production, 33–34
 sulfonylurea effects, 52
 liver disease
 non-alcoholic fatty, 155, 287
 prescribing, 35, 337–340
 lixisenatide, 137, 139, 143–145, 151, 336, 338
 insulin glargine and, 134, 141
 low-glucose suspend, 223
 low-income (under-resourced) countries, 291, 311, 316–318
 LRC-CPPT, 262

M

malignancy, *see* cancer
 marketing authorisation, 14
 MARLINA-T2D, 90
 mechanism of action, 3–4
 alpha glucosidase inhibitors, 230
 DPP-4 inhibitors, 68
 glitazones, 240–241
 GLP-1 receptor agonists, 131
 imeglimin, 288
 insulin, 163–164
 metformin, 32–34
 SGLT-1 inhibitors, 97
 sulfonylureas, 51–52
 MEDI0382 (cotadutide), 274, 285–286
 Medicines and Healthcare Products Regulatory Agency (MHRA), 10, 18
 Medtronic devices, 221, 223, 224–225
 meglitinides, 61–65, 315, 336, 339–340

membrane channels, 4
 meta-analysis, network, 25–26
 metabolism, 6–7
 elderly, 349
 liver disease affecting, 339
 short-acting insulins, factors affecting, 180
 metformin (dimethylbiguanide), 4,
 30–48, 124, 289
 DPP-4 inhibitors with, 75–79
 GLP-1 receptor agonists compared with, 140
 guidelines, 300, 301, 303, 306, 307, 317
 pregnancy and, 35, 311–313
 prescribing, 37, 38, 46, 328, 334, 335, 339,
 347–348, 348, 351–352
 in liver disease, 35, 338, 339
 in renal impairment, 35, 334, 335
 type 1 diabetes, 45, 271, 308
 see also biguanides
 MHRA (Medicines and Healthcare Products
 Regulatory Agency), 10, 18
 microdosing (phase 0 trials), 8, 11
 miglitol, 221, 229, 230
 multiagonists, 274–293
 muraglitazar, 252–253

N

naltrexone/bupropion, 257, 268–269
 nateglinide, 61, 62, 63–64, 315, 336, 338, 339–340
 National Institute for Health and Care
 Excellence, *see* NICE
 NAVIGATOR, 62, 63–64
 nephropathy, *see* kidney disease
 network meta-analysis, 25–26
 NICE (National Institute for Health and Care
 Excellence), 298–300, 308
 guidelines
 insulin pumps, 225–226
 liraglutide, 154, 205
 pregnancy, 11
 type 1 diabetes, 308
 type 2 diabetes, 294, 296, 298–300, 318
 pharmacoeconomics, 21, 22
 NNC0090-2746, 285
 nonadherence, 329–330
 non-alcoholic fatty liver disease, 155, 287
 NPH (isophane) insulin, 166, 167–168, 172, 177,
 184, 195, 197, 198, 200, 201, 206, 207, 208,
 210, 311, 312, 318

O

obesity and overweight, 153–155
 cardiovascular risk in type 2 diabetes, 341
 drug therapy, 257, 265–270, 271

see also weight gain; weight loss
 older people (elderly), prescribing, 322,
 327, 349–350
 omarigliptin, 74
 Onset trials, 187–188
 Oral-Lyn, 192
 ORIGIN, 198–199, 202
 orlistat, 257, 266–267, 271
 outcome trials, *see* trials
 overweight, *see* obesity and overweight; weight gain

P

pancreas
 artificial (APS), 223, 224, 225
 beta cells, 51, 52, 61, 131, 162, 261, 275, 276
 cancer, 80–81, 143, 146, 147, 149
 GLP-1 receptor agonist actions, 131
 islet cells, *see* islet cells
 pancreatitis, 21, 80–81, 143, 145, 146, 147, 149
 Parkinson's disease, 156
 'patch' pump, 216
 patient
 education, *see* education
 as factor in therapeutic inertia, 324, 325–326
 PEG, *see* polyethylene glycol
 peptide fusion molecules, 277
 peroxisome proliferator-activated receptors
 (PPARs), 4, 240, 245, 252, 253
 PEX168, 136
 pharmacodynamics, 2, 3–5
 DPP-4 inhibitors, 69–75
 GLP-1 receptor agonists, 132–136
 insulin, 15
 insulin analogues, modifying, 197
 SGLT2 inhibitors, 97–100
 see also mechanism of action
 pharmacoeconomics, 2, 21–26
 future developments, 27–28
 pharmacogenomics, 27, 353
 pharmacokinetics, 5–7
 DPP-4 inhibitors, 69–75
 elderly, 349–350
 glitazones, 241
 GLP-1 receptor agonists, 132–136
 insulin, 14–15, 165–170
 insulin analogues, modifying, 197
 metformin, 35
 renal impairment and, 335
 SGLT2 inhibitors, 97–100
 sulfonylureas, 52–53
 young people, 348–349
 pharmacology, 3–7
 alpha glucosidase inhibitors, 230–231

- bromocriptine, 265
 - colesevelam, 260–261
 - DPP-4 inhibitors, 68–75
 - future developments, 26–27
 - glitazones, 240
 - GLP-1 receptor agonists, 131–136
 - imeglimin, 288
 - metformin, 32–36
 - multiagonists, 277
 - orlistat, 266
 - phentermine/topiramate, 269
 - pramlintide, 258
 - SGLT2 inhibitors, 96–100
 - sulfonylureas, 51–53
 - pharmacovigilance, 19–21
 - active, 20–21
 - future developments, 27
 - human insulin and hypoglycaemia, 170
 - passive, 19–20
 - phase 0–4 trials, 8, 10–11
 - phase 1 and 2 metabolism, 7
 - phenformin, 31–32
 - phentermine/topiramate, 257, 269–270
 - phlorizin, 15, 96
 - pioglitazone, 60, 72, 78, 239, 240, 241, 242, 245, 246, 247–250, 251–252, 254, 301, 315, 328, 335, 338, 339, 346
 - PIONEER series, 102, 138–139, 139–140, 144, 149–150, 152
 - plasma protein binding, 5
 - polyethylene glycol (PEG) addition
 - insulin lispro, 205
 - loxenatide, 136
 - polypharmacy, 322, 326–329
 - poorer (under-resourced) countries, 291, 311, 316–318
 - pork insulin, 169
 - PPARs (peroxisome proliferator-activated receptors), 4, 240, 245, 252, 253
 - pramlintide, 257, 258–260, 271
 - preclinical development, 8–9
 - pregnancy, 311–313, 347–349
 - closed-loop insulin systems, 227
 - metformin and, 35, 311–313, 347–349
 - prescribing, 347–349
 - prescribing (incl. prescribing points), 322–356
 - alpha glucosidase inhibitors, 232
 - in cardiovascular disease, 340–347
 - case examples, 350–353
 - DPP-4 inhibitors, 70, 72, 73, 75, 89–91
 - glitazones/thiazolidinediones, 244, 245, 250, 335, 339, 346
 - GLP-1 receptor agonists, 133–134, 134, 135, 136, 147, 152, 322, 335, 338, 340, 345, 346, 352
 - good, 323
 - insulin, 331, 333, 337, 340, 346, 349, 350–351
 - biosimilar, 18
 - devices, 215, 217, 218, 219
 - human/animal, 167, 169, 171, 172
 - long-acting, 198, 200, 201, 203
 - short-acting, 183, 184, 186, 188
 - in kidney disease/renal impairment, 35, 333–337
 - in liver disease, 35, 337–340
 - meglitinides, 62, 336, 339–340
 - metformin, 35, 37, 38, 46, 328, 334, 335, 339, 347–348, 348, 351–352
 - orlistat, 267
 - pramlintide, 260
 - in pregnancy, 347–349
 - SGLT2 inhibitors, 101, 103, 104, 322, 334, 336, 338, 340, 345, 347
 - sulfonylureas, 52, 53, 55, 60, 62, 65, 328, 334, 336, 339–340
 - PROactive, 246, 247–248
 - prodrug, insulin, 197
 - PRONTO-T1D and T2D, 188–189
 - protamine zinc insulin, 166, 167
 - proteins
 - insulin actions, 164
 - plasma, drug binding to, 5
- ## R
- Ramadan, 315–316, 317
 - real-time continuous glucose monitoring, 217, 219, 221, 226
 - receptors (action on), 3–4
 - RECORD, 243, 244, 245–247
 - regulations (regulatory status/approval), 2, 9–10
 - DPP-4 inhibitors, 82
 - imeglimin, 290
 - insulin, 14–17
 - biosimilar, 17
 - SGLT2 inhibitors in in type 1 diabetes, 123
 - REMOVAL, 40, 45–46
 - renal..., *see* kidney
 - repaglinide, 61–62, 62, 315, 336, 338, 339
 - retrospective continuous glucose monitoring, 219
 - REWIND, 144, 148–149, 152
 - RG7697, 285
 - rosiglitazone, 37, 53, 54, 239–245, 247, 251
 - cardiovascular effects, 13, 243–244, 247

S

safety (incl. adverse/side effects), 7–8
 alpha glucosidase inhibitors, 232
 cardiovascular, *see* cardiovascular safety
 DPP-4 inhibitors, 79–82
 glitazones, 242–245
 GLP-1 receptor agonists, 142–143
 imeglimin, 288–289
 insulin analogues, 299
 metformin, 37–38
 pramlintide, 260
 pregnancy and, 312
 SGLT2 inhibitors, 103–105
 sulfonylureas, 55
 tirzepatide, 279, 280
 SAR425899, 286
 saroglitazar, 253
 SAVOR TIMI 53 study, 81, 83, 84, 86, 89, 346
 saxagliptin, 70–71, 76–77, 80, 83, 84, 89, 306, 334, 336, 338, 346
 SCALE, 153–155
 SCORED, 100, 111, 113
 SCORED-WHF, 118
 Scottish Intercollegiate Guidelines Network (SIGN), 36, 91–92, 226, 296, 297, 298–299, 300, 301, 308–310, 311, 318
 SELECT, 154–155
 self-monitoring of glucose, *see* glucose monitoring
 semaglutide, 13, 102, 132, 135–136, 138, 139, 144, 146–147, 149–150, 154–155, 155, 280, 334, 336, 338
 semilente, 166, 167
 sensitivity analysis, 24–25
 SGLT, *see* sodium glucose co-transporters
 side effects, *see* safety
 SIGN (Scottish Intercollegiate Guidelines Network), 36, 91–92, 226, 296, 297, 298–299, 300, 301, 308–310, 311, 318, 318–319
 sitagliptin, 54, 69–70, 76–77, 79, 86–87, 90, 139, 289, 334, 336, 338
 SMARTTEST, 124
 smoking, 341
 sodium glucose co-transporters (SGLTs), 96–97
 SGLT1 inhibitor, 100
 SGLT2 inhibitors, 4, 26, 95–129, 139, 299, 301, 305, 307
 combined with GLP-1 receptor agonists, 156
 prescribing, 101, 103, 104, 322, 334, 336, 338, 340, 345, 347

type 2 diabetes, 124, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 352, 353
 SOLOIST-WHF, 100, 117
 Somogyi effect, 173
 sotagliflozin, 96, 100, 111, 113, 117, 118, 120, 121, 123, 125
 SPREAD-DIMCAD, 40, 41–42
 standard gamble, 23
 STENO-2, 342
 STOP-NIDDM, 232–234, 235–236, 237
 STOPP/START tool, 327–328
 structured education, 177, 191, 210, 217, 308
 substitution, biosimilars, 18
 sulfonylureas, 49–60, 61, 63, 65, 250
 guidelines, 301, 317
 in kidney disease, 314–315
 in liver disease, 339–340
 prescribing, 52, 53, 55, 60, 62, 65, 328, 334, 336, 338, 339–340
 SURMOUNT series, 283–284
 SURPASS series, 279–282
 SUSTAIN series, 102, 138, 139, 144, 146–147
 SWITCH 1 and 2, 202, 208
 SYNERGY-NASH, 283

T

Tandem system, 224
 taspoglutide, 136
 Technosphere insulin, 190
 TECOS, 81, 83, 86–87, 88, 90, 91
 teneligliptin, 74
 tesaglitazar, 253
 therapeutic inertia, 323–326
 thiazolidinediones, *see* glitazones
 thyroid cancer, 9, 142–143, 149, 150, 151
 TIDE, 247
 time-action profiles, insulin, 166–167, 170, 171, 171–172, 180, 201
 time in range, 221–222
 time trade-off, 23
 TIMES series, 289–290
 tirzepatide, 274, 278–284, 291
 tolbutamide, 50, 56
 topiramate/phentermine, 257, 269–270
 TOSCA.IT, 60, 63–64, 246, 250
 transplantation
 pancreatic or islet cell, 333
 post-transplant diabetes, 315, 316
 trelagliptin, 74
 trials, clinical (incl. outcome), 8, 11–12
 alpha glucosidase inhibitors, 232–237
 DPP-4 inhibitors, 75–79, 82–91

glitazones, 241–242, 243–245, 245–252
 GLP-1 receptor agonists, 143–155
 meglitinides, 62–63
 metformin, 38–44
 SGLT2 inhibitors, 105–119
 sulfonylureas, 56–60, 62–63
 triple agonists, 287, 291
 TRIPOD, 251
 troglitazone, 239, 251
 type 1 diabetes, 270–271, 308–311
 guidelines, 296–297, 308–311, 312–313, 317
 insulin, 176, 308–311
 insulin analogues
 long-acting, 201, 202, 204, 205, 206,
 207, 209, 210
 short-acting, 182, 183, 184, 185,
 187, 188, 190
 insulin devices, 217, 218, 222, 223,
 225–226, 227
 metformin, 45, 271, 308
 pramlintide, 258, 259, 259–260, 260, 271
 SGLT2 inhibitors, 119–123, 125
 therapeutic journey (case), 350–351
 other drugs, 270–271
 type 2 diabetes, 271, 298–308, 312–313, 317
 cardiovascular risk factors, 341
 glitazones, *see* glitazones
 guidelines, 296, 298–308, 317, 318, 319
 hyperglycaemia management guide-
 lines, 295–296
 insulin, 177, 302, 304, 306
 insulin analogues (long-acting), 207–208, 302
 prevention, 42–44, 232–235, 251–252, 254
 SGLT2 inhibitors, 124, 298, 299, 300,
 301, 302, 303, 304, 305, 306,
 307, 352, 353
 therapeutic journey (case), 351–353
 other drugs, 259–260, 271

U

UGDP, 50, 56
 UK, regulatory process, 10, 18
 UKPDS, 32, 38–39, 40, 50, 54, 55, 56, 57–58,
 63–64, 174–175, 231, 342–344
 under-resourced countries, 291, 311, 316–318
 urinary infections, 103
 utility values, 23
 see also cost–utility analysis

V

VADT, 295, 342–344
 VERIFY, 75–79
 VERTIS series, 99, 100, 106, 107, 109, 114, 118
 vildagliptin, 5, 70, 71–72, 75–79, 80, 88, 334,
 338
 VIVID, 88
 voglibose, 229, 231, 233, 234–235
 volume of distribution in liver disease, 339

W

weight gain
 insulin, 176
 sulfonylureas, 55
 see also obesity and overweight
 weight loss/reduction, 102, 137–140, 143,
 153–155, 266, 267, 268, 269–270, 285, 286
 see also antiobesity drugs
 WHO (World Health Organization) guidelines,
 294, 298, 316

X

XENDOS, 267

Z

zinc-suspension insulin, 166–167

